Interactive Investor
>>

Shield Therapeutics (LSE:STX) Share Price

STX

Shield Therapeutics

UK company

Right Arrow 1

Healthcare

Right Arrow 2

Drug Manufacturers - Specialty & Generic

 / 

- / -
-
- / -
-
-
-

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XLON

-

Updated: -

Research

News & analysis

Regulatory news

Loading...

Times are shown in BST, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.Shield Therapeutics PLC is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.

LSE:STX

GB00BYV81293

GBX

Loading...

Loading Comparison

Latest STX News

STX Regulatory News